Literature DB >> 27664263

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

M Dreyling1, M Ghielmini2, S Rule3, G Salles4, U Vitolo5, M Ladetto6.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27664263     DOI： 10.1093/annonc/mdw400

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  51 in total

1.  Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.

Authors:  Andres Forero-Torres; Radhakrishnan Ramchandren; Abdulraheem Yacoub; Michael S Wertheim; William J Edenfield; Paolo Caimi; Martin Gutierrez; Luke Akard; Carolina Escobar; Justin Call; Daniel Persky; Swaminathan Iyer; Douglas J DeMarini; Li Zhou; Xuejun Chen; Fitzroy Dawkins; Tycel J Phillips
Journal:  Blood       Date:  2019-02-25       Impact factor: 22.113

2.  Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party.

Authors:  L Bento; A Boumendil; H Finel; S Le Gouill; S Amorim; H Monjanel; R Bouabdallah; J O Bay; E Nicolas-Virelizier; G McQuaker; G Rossi; R Johnson; A Huynh; P Ceballos; A Rambaldi; E Bachy; R Malladi; K Orchard; D Pohlreich; H Tilly; F Bonifazi; X Poiré; F Guilhot; A Haenel; C Crawley; B Metzner; J Gribben; N H Russell; G Damaj; K Thomson; P Dreger; S Montoto
Journal:  Bone Marrow Transplant       Date:  2017-05-22       Impact factor: 5.483

3.  Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R2) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.

Authors:  Koji Izutsu; Yosuke Minami; Noriko Fukuhara; Yasuhito Terui; Tatsuro Jo; Go Yamamoto; Takayuki Ishikawa; Tsutomu Kobayashi; Toru Kiguchi; Hirokazu Nagai; Tomoko Ohtsu; Stacey Kalambakas; Pierre Fustier; Shuichi Midorikawa; Kensei Tobinai
Journal:  Int J Hematol       Date:  2019-12-19       Impact factor: 2.490

4.  The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.

Authors:  Lorenz Selberg; Peter Stadtherr; Sascha Dietrich; T Hien Tran; Thomas Luft; Ute Hegenbart; Andrea Bondong; Julia Meissner; Nora Liebers; Michael Schmitt; Anthony Dick Ho; Carsten Müller-Tidow; Peter Dreger
Journal:  Bone Marrow Transplant       Date:  2020-06-18       Impact factor: 5.483

5.  Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.

Authors:  Stefan Alig; Vindi Jurinovic; Mohammad Shahrokh Esfahani; Sarah Haebe; Verena Passerini; Johannes C Hellmuth; Erik Gaitzsch; William Keay; Natyra Tahiri; Anna Zoellner; Andreas Rosenwald; Wolfram Klapper; Harald Stein; Alfred Feller; German Ott; Annette M Staiger; Heike Horn; Martin L Hansmann; Christiane Pott; Michael Unterhalt; Christian Schmidt; Martin Dreyling; Ash A Alizadeh; Wolfgang Hiddemann; Eva Hoster; Oliver Weigert
Journal:  Blood Adv       Date:  2020-09-22

Review 6.  Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.

Authors:  Sohita Dhillon
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

7.  Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study).

Authors:  Tamás Schneider; András Rosta; Hajna Losonczy; Gáspár Radványi; György Ujj; Miklós Egyed; Árpád Illés; János Jakucs; László Szerafin; Zoltán Gasztonyi; Tamás Masszi; János Iványi; Judit Demeter; Péter Dombi; Antal Tóth; Zita Borbényi
Journal:  Pathol Oncol Res       Date:  2017-04-21       Impact factor: 3.201

Review 8.  Lenalidomide: A Review in Previously Treated Follicular Lymphoma.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

Review 9.  [Lymphoma in rheumatic diseases].

Authors:  A Rubbert-Roth; J T Bittenbring; G Assmann
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

10.  Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Authors:  Shigeru Kusumoto; Luca Arcaini; Xiaonan Hong; Jie Jin; Won Seog Kim; Yok Lam Kwong; Marion G Peters; Yasuhito Tanaka; Andrew D Zelenetz; Hiroshi Kuriki; Günter Fingerle-Rowson; Tina Nielsen; Eisuke Ueda; Hanna Piper-Lepoutre; Gila Sellam; Kensei Tobinai
Journal:  Blood       Date:  2018-10-19       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.